Actylis partnering that has a generic pharmaceutical maker by choosing an API, various decades before the expiration of a composition of matter patent, for future sector revenue;Phase 2: Forecast a list of probable/extending MRM pairs in step with the listing obtained in phase one after which coupled it Using the appropriate (bio-) transformation